News

CURE8h
Understanding Therapeutic Options for ER+/HER2- Metastatic Breast Cancer
Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...
CURE9h
FDA Approves Stoboclo and Osenvelt as Biosimilars Across Some Cancers
Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...
The Manila Times4h
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
The global Phase 3 Cosmic study is an open-label, randomized, active-controlled study in patients aged 2 to <7 years.
Center for Biosimilars3h
Two More Pairs of Denosumab Biosimilars Enter US Market
The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...
Cancer Therapy Advisor20h
Denosumab Biosimilars Now Available
The denosumab biosimilars Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) are now available in the US.